Inhalable Spray Dried Pro-Liposome Powder Containing Budesonide for Pulmonary Delivery
DOI:
https://doi.org/10.37285/ijpsn.2021.14.4.3Abstract
Budesonide is an anti-asthmatic agent which is used to control the symptoms of asthma like bronchospasm, oedema. Drug delivered to lung through inhalation will provide systemic and local drug delivery at lower dose in chronic and acute diseases. Dry powder inhalers are the best choice for targeting the anti-asthmatic drugs through pulmonary route. The objective of the present study is to prepare inhalable lipid coated budesonide microparticles by spray drying method so effective delivery of budesonide to the lungs can be achieved. The microparticles in the form of dry powder were obtained by either spray drying liposomal drug suspension or lipid drug suspension. The liposomes were initially prepared by solvent evaporation method using Hydrogenated Soyabean Phosphatidylcholine and Cholesterol (1:1, 1:2, 2:1) as lipid carrier and then spray dried later with mannitol as bulking agent at different lipid to diluent ratio (1:1.25, 1:2.5 & 1:5). The liposomes and liposomal dry powder were evaluated for vesicle size, % entrapment efficiency, in vitro drug release studies, powder characteristics, aerosol performance and stability studies. The liposomes prepared showed vesicle size (2-8 µm), Entrapment efficiency (92.22%) at lipid: drug ratio of (2.5:1) and observed 80.41 % drug release in 24 hrs. Pro-liposomes prepared by spray drying of liposomal drug suspension (LSD1) showed emitted dose, mean mass aerodynamic diameter, geometric standard deviation and fine particle fraction of 99.01%, 3.12 µm, 1.78 and 43.5% along with good powder properties. The spray dried powder was found to be stable at 4 ± 2 °C & 65% ± 5 % RH. The inhalable microparticles containing Budesonide containing lipid dry powder was successfully prepared by spray drying method that showed good aerodynamic properties and stability with mannitol as diluent. The microparticles produced with this novel approach could deliver drug on target via inhalation route and also ease manufacture process at large scale in fewer production steps.
Downloads
Metrics
Keywords:
Pulmonary drug delivery, Dry powder inhalation, Budesonide, Spray drying technique, Liposomes
Published
How to Cite
Issue
Section
References
Andersson and Brattsand (1982). Protective effects of the glucocorticoid budesonide on lung anaphylaxis in actively sensitized guinea pigs: inhibition of IgE but not of IgG mediated anaphylaxis. British journal of pharmacology 76(1): 139-4.
Bergstrand et al., (1984). Inhibitory effect of glucocorticoids on Anti-IgE induced histamine release from human basophilic leukocytes: evidence for a dual mechanism of action. Allergy 39(3): 217-30.
Boraey et al., (2013). Improvement of the dispersibility of spray dried budesonide powders using leucine in an ethanol-water cosolvent system. Powder technology 236: 171-8
Bowler et al., (1992). Corticosteroids in acute severe asthma: effectiveness of low doses. Thorax 47(8): 584–587.
Cox et al., (1991). Promotion of eosinophil survival by human bronchial epithelial cells and its modulation by steroids., American Journal of Respiratory Cell and Molecular Biology 4(6): 525-31.
Dal Negro (2015). Dry powder inhalers and the right things to remember: A concept review. Multi-disciplinary Respiratory Medicine 10(1): 2-5.
Danaei et al., (2018). Impact of particle size and polydispersity index on the clinical applications of lipid nanocarrier system, Pharmaceutics 10(2): 57.
De (2003). An air classifier technology ACT in dry powder inhalaltion part 1. Intorduction of a novel force distribution concept FDC explaining the performancr of air classifier on adhesive mixtures. International Journal of Pharmaceutics (2): 187-200.
El-Sherbiny et al., (2015). Inhaled nano- and microparticles for drug delivery. Global Cardiology Science and Practtice. (1): 2.
Emami et al., (2016). Liposomes as carrier vehicles for functional compounds in food sector. Journal of Experimental Nanoscience 11(9): 737-759.
Gilbert et al., (1991). Aerosol and intraperitoneal administration of ribavirin and ribavirin triacetate: Pharmacokinetics and protection of mice against intracerebral infection with influenza A/WSN virus. Antimicrobial Agents and Chemotherapy 35(7): 1448-53.
Gonda (2004). Targeting by deposition, Pharmaceutical inhalation aerosol technology, 2nd Edition, Marcel Dekker, New York.
Guo et al., (2003). Chitosan coated liposomes: characteri-sation and interation with leuprolide. International Journal of Pharmaceutics 260(2): 167-73.
Kim et al., (20110) Asthma. Allergy, Asthma and Clinical Immunology 7(Suppl 1): S2
Meenach et al., (2014). High-Performing Dry Powder Inhalers of Paclitaxel DPPC / DPPG Lung Surfactant-Mimic Multi-functional Particles in Lung Cancer : Physicochemical Characterization, In vitro Aerosol Dispersion, and Cellular Studies. American Association of Pharmaceutical Scientist 15(6): 1574-87.
Meenach et al., (2013). Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphos-phatidylcholine (DPPC) and dipalmitoylphosphatidy-lethanolamine poly (ethylene glycol) (DPPE-PEG) microparticles and nanoparticles. International Journal of Nanomedicine 8: 275-93.
Miller et al., (2015). Physical Characterization of Tobramycin Inhalation Powder: I. Rational Design of a Stable Engineered-Particle Formulation for Delivery to the Lungs. Molecular Pharmaceutics 12(8): 2582-93.
Myers et al., (1992). A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged, neutropenia. Leukemia Lymphoma 8(2): 229-33.
Nirale et al., (2009). Fluticasone propionate liposome for pulmonary delivery, Indian Journal of Pharmaceutical Science, 71(6), 709-711.
Parmar et al., (2010). Development and Evaluation of Inhalational Liposomal System of Budesonide for Better Management of Asthma. Indian Journal of Pharmaceutical Science, 72(4): 442-448.
Parthasarathy et al., (1999). Aerosol delivery of liposomal all-trans-retinoic acid to the lungs. Cancer Chemotherapy and Pharmacology 43(4): 277–83.
Phillipps (1990). Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respiratory Medicines 84:19–23.
Pragati et al., (2009). Solid Lipid Nanoparticles : A Promising Drug Delivery Technology. International Journal of Pharmaceutical Science and Nanotechnology 2(2): 509–16.
Ross et al., (2010). Excess lung function decline in fold miners following pulmonary tuberculosis. Thorax 65(11): 1010-1015.
Salvaggio (1994). Inhaled particles and respiratory disease. Journal of Allergy and Clinical Immunology 94 (Suppl. 18): 304-9.
Sarinho (2004). Inhaled budesonide for acute asthma- is it all a question of time and space? Journal dePadiatria (Rio J) 80(2): 88-9.
Shrestha et al., (2014). Lipid based drug delivery system. International Journal of Pharmaceutics 1-10.
Shruthi et al., (2014). Proliposomes As a Novel Drug Delivery System for the Improvement of Vesicular Stability. International Journal of Research in Pharmaceutical and Nano Sciences 3(4): 326–36.
Suntres and Shek (1996). Alleviation of paraquat-induced lung injury by pretreatment with bifunctional liposomes containing α-tocopherol and glutathione. Biochemical and Pharmacology 52(10): 1515-20.
Toogood et al., (1989). Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. Journal of Allergy and Clinical Immunology 84(5 PART 1): 688–700.
Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L(1999). Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clinical infectious disease 29(6): 1402–7.
